Cardiopulmonary Exercise Testing is an operative way to assess patient’s cardiovascular & pulmonary diseases. The tests involve blood pressure, electrocardiography analysis, etc. It is used for assessing the exercise capacity and predict outcome in patients with heart failure & other cardiac conditions. It provides a valuation of integrative exercise responses to the patients suffering from cardiovascular, pulmonary, and skeletal muscle systems. It helps cardiac patients to control & manage their heart conditions. It is a low risk investigation which permits precise, vibrant valuation of cardiac and pulmonary performance.
According to study, “Cardiopulmonary Exercise Testing Market Research Report by Product (Echocardiogram, Pulse Oximeters, Stress Blood Pressure Monitors, and Others), End-user (Hospital/Clinical Laboratories, Diagnostic Centers, Ambulatory Centers, and Others), and Region (APAC, Europe, North America, RoW)-Global Forecast to 2023” the key companies operating in the cardiopulmonary exercise testing market are COSMED srl, Nihon Kohden Corporation, GE Healthcare, Cardinal Health, Masimo Corporation, Halma plc., Hill-Rom Holdings, Inc., Schiller AG, Vyaire Medical, Inc., Koninklijke Philips N.V., MGC Diagnostics Corporation. The key strategies that players provide to influence market growth include research & development, vide product portfolio and strategic business procurements.
Based on product type, cardiopulmonary exercise testing market is segmented into Cardiopulmonary Exercise Testing (CPET) Systems, pulse oximeters, Single-Photon Emission Computed Tomography (SPECT), stress blood pressure monitors and echocardiogram. CPET segment dominate the market owing to rise in incidence of ischemia. In addition, based on end-user, market is segmented into hospitals & clinics, ambulatory centres, diagnostic centres and others. The rise in rate of cardiovascular disorders globally has supported the cardiopulmonary exercise testing market growing extensively.
The hospitals & clinics segment is expected to witness substantial growth due to rise in treatment of heart diseases & coronary diseases and growth in need for diagnosis during the forecast period.
The cardiopulmonary exercise testing market is driven by rise in cardiovascular & respiratory system-related diseases, followed by increase in patient population, rise in adoption of early diagnostic practices, increase in healthcare spending, high disposable income per individual, rise in demand for high value low volume product, growth in developments in advanced medical treatment options, increase in awareness programs and growth in research & development (R&D). However, growth in regulatory affairs, lack of expertise among healthcare professionals and high cost of instruments may impact the market. Moreover, rise in emerging markets and growth in innovations in the new product launches are key opportunities for market.
Based on geography, the American region holds major share, followed by European region in cardiopulmonary exercise testing market owing to rise in prevalence of coronary artery diseases (angina pectoris and acute myocardial infarction), presence of major manufacturers, rise in availability of cutting-edge medical technology, improvement in economies and rise in government initiatives in the region. The Asian-Pacific region is expected to witness lucrative growth due to low manufacturing cost, rise in investments by the American & European market giants and growth in healthcare infrastructure over the forecast period. The global market is estimated to reach the valuation of US $2248.21 million by growing at a CAGR of 5.75% during the forecast period (2018- 2023).
To know more, click on the link below:-
Ankur Gupta, Head Marketing & Communications